JP2020511529A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511529A5
JP2020511529A5 JP2019568594A JP2019568594A JP2020511529A5 JP 2020511529 A5 JP2020511529 A5 JP 2020511529A5 JP 2019568594 A JP2019568594 A JP 2019568594A JP 2019568594 A JP2019568594 A JP 2019568594A JP 2020511529 A5 JP2020511529 A5 JP 2020511529A5
Authority
JP
Japan
Prior art keywords
composition
stimulus
vector
cell
payload
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019568594A
Other languages
English (en)
Japanese (ja)
Other versions
JP7341900B2 (ja
JP2020511529A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/020741 external-priority patent/WO2018161017A1/en
Publication of JP2020511529A publication Critical patent/JP2020511529A/ja
Publication of JP2020511529A5 publication Critical patent/JP2020511529A5/ja
Priority to JP2023139792A priority Critical patent/JP2023164900A/ja
Application granted granted Critical
Publication of JP7341900B2 publication Critical patent/JP7341900B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019568594A 2017-03-03 2018-03-02 免疫療法のためのcd19組成物及び方法 Active JP7341900B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023139792A JP2023164900A (ja) 2017-03-03 2023-08-30 免疫療法のためのcd19組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762466601P 2017-03-03 2017-03-03
US62/466,601 2017-03-03
US201762484052P 2017-04-11 2017-04-11
US62/484,052 2017-04-11
PCT/US2018/020741 WO2018161017A1 (en) 2017-03-03 2018-03-02 Cd19 compositions and methods for immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023139792A Division JP2023164900A (ja) 2017-03-03 2023-08-30 免疫療法のためのcd19組成物及び方法

Publications (3)

Publication Number Publication Date
JP2020511529A JP2020511529A (ja) 2020-04-16
JP2020511529A5 true JP2020511529A5 (enrdf_load_stackoverflow) 2021-04-15
JP7341900B2 JP7341900B2 (ja) 2023-09-11

Family

ID=63371272

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019568594A Active JP7341900B2 (ja) 2017-03-03 2018-03-02 免疫療法のためのcd19組成物及び方法
JP2023139792A Pending JP2023164900A (ja) 2017-03-03 2023-08-30 免疫療法のためのcd19組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023139792A Pending JP2023164900A (ja) 2017-03-03 2023-08-30 免疫療法のためのcd19組成物及び方法

Country Status (8)

Country Link
EP (1) EP3589646A4 (enrdf_load_stackoverflow)
JP (2) JP7341900B2 (enrdf_load_stackoverflow)
KR (1) KR102746901B1 (enrdf_load_stackoverflow)
CN (1) CN110831961B (enrdf_load_stackoverflow)
AU (2) AU2018227583B2 (enrdf_load_stackoverflow)
CA (1) CA3055202A1 (enrdf_load_stackoverflow)
SG (2) SG11201907922PA (enrdf_load_stackoverflow)
WO (1) WO2018161017A1 (enrdf_load_stackoverflow)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
CN111107866A (zh) 2017-06-12 2020-05-05 黑曜石疗法公司 用于免疫疗法的pde5组合物和方法
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス, インク.Flodesign Sonics, Inc. 音響トランスデューサドライバ及びコントローラ
AU2018385756A1 (en) * 2017-12-15 2020-07-09 Aleta Biotherapeutics Inc. CD19 variants
CN119752803A (zh) * 2018-08-01 2025-04-04 南克维斯特公司 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统
EP3856910B1 (en) * 2018-09-24 2024-11-20 Merck Sharp & Dohme LLC Expression vectors for eukaryotic expression systems
IL277414B2 (en) * 2018-11-06 2025-04-01 Immunitybio Inc NK–92 cells with chimeric antigen receptor modification
US12109238B2 (en) 2018-11-06 2024-10-08 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells
CN118497276A (zh) * 2018-11-07 2024-08-16 阿库斯股份有限公司 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途
EP3894011A1 (en) * 2018-12-11 2021-10-20 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
CN116479022A (zh) * 2018-12-12 2023-07-25 中南大学 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
WO2020123691A2 (en) 2018-12-12 2020-06-18 Kite Pharma, Inc Chimeric antigen and t cell receptors and methods of use
WO2020156335A1 (zh) * 2019-01-29 2020-08-06 上海交通大学 一种嵌合抗原受体及其应用
CN113423720A (zh) 2019-02-04 2021-09-21 国立大学法人爱媛大学 CAR文库和scFv的制造方法
AU2020224160A1 (en) * 2019-02-21 2021-08-26 John M. LUK Artificial immunosurveillance chimeric antigen receptor (AI-CAR) and cells expressing the same
CN113811549A (zh) 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白
US20220144917A1 (en) 2019-03-01 2022-05-12 Universität Für Bodenkultur Wien Stabilized extracellular domain of cd19
MX2021010670A (es) 2019-03-05 2021-11-12 Nkarta Inc Receptores de antigeno quimerico dirigidos a cd19 y usos de los mismos en inmunoterapia.
BR112021017770A2 (pt) * 2019-03-08 2021-11-16 Obsidian Therapeutics Inc Composições e métodos de cd40l para regulação ajustável
BR112021017744A2 (pt) * 2019-03-08 2021-11-16 Obsidian Therapeutics Inc Composições e métodos de cd40l para regulação ajustável
WO2020190771A1 (en) * 2019-03-15 2020-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
PE20212369A1 (es) 2019-04-26 2021-12-21 Allogene Therapeutics Inc Receptores de antigenos quimericos resistentes a rituximab y usos de estos
CN110079504A (zh) * 2019-05-06 2019-08-02 山东大学第二医院 一种含有不稳定结构域的car-t细胞及其制备方法和调节car-t细胞功能方法
CN110075275B (zh) * 2019-05-15 2023-03-24 苏州大学 IL-36β的应用
EP3976196A4 (en) * 2019-05-29 2023-06-14 Orbis Health Solutions, LLC Delivery vectors and particles for expressing chimeric receptors and methods of using the same
BR112021025022A2 (pt) * 2019-06-12 2022-02-22 Obsidian Therapeutics Inc Composições de ca2 e métodos para regulação ajustáveis
CN110818803B (zh) * 2019-07-24 2023-01-03 浙江启新生物技术有限公司 分泌表达il15ra-il15融合蛋白、ccl21趋化因子的嵌合抗原受体-t细胞及应用
WO2021034952A1 (en) * 2019-08-19 2021-02-25 Elpis Biopharmaceuticals Anti-cd19 antibodies and uses thereof
CA3149543A1 (en) * 2019-08-27 2021-03-04 Donald M. O'rourke Synthetic cars to treat il13r.alpha.2 positive human and canine tumors
WO2021040736A1 (en) 2019-08-30 2021-03-04 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (en) * 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CA3150224A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
CA3154280A1 (en) * 2019-10-11 2021-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting cd13 and tim-3 with car t cells to treat acute myeloid leukemia
AU2020394427A1 (en) * 2019-11-27 2022-07-14 The Trustees Of The University Of Pennsylvania Anti-CD3 scFv and cytokine producing artificial antigen presenting cells
AU2020393906A1 (en) * 2019-11-27 2022-06-23 Board Of Regents, The University Of Texas System Large-scale combined car transduction and CRISPR gene editing of T cells
MX2022008415A (es) * 2020-01-08 2022-08-08 Obsidian Therapeutics Inc Composiciones y metodos para la regulacion ajustable de la transcripcion.
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
KR20220167276A (ko) * 2020-03-10 2022-12-20 매사추세츠 인스티튜트 오브 테크놀로지 NPM1c-양성 암의 면역치료를 위한 조성물 및 방법
EP4204560A4 (en) * 2020-09-02 2024-10-16 Nkarta, Inc. ENHANCED EXPANSION AND CYTOTOXICITY OF MODIFIED NATURAL KILLER CELLS AND RELATED USES
EP4209593A4 (en) * 2020-09-04 2024-10-09 Heartseed Inc. IPS CELL QUALITY IMPROVING AGENT, METHOD FOR PRODUCING IPS CELLS, IPS CELLS, AND COMPOSITION FOR PRODUCING IPS CELLS
US20240002479A1 (en) * 2020-11-23 2024-01-04 The Regents Of The University Of Michigan Single-chain antibody against flavivirus ns1 protein
CN112795543B (zh) * 2021-02-04 2022-09-27 华中农业大学 杂交瘤细胞株及其分泌的抗草鱼IL-15Rα单克隆抗体和应用
CN113403274B (zh) * 2021-06-28 2023-11-10 上海睿臻迈生物医疗科技有限公司 细胞治疗组合物及其制备方法和作为过敏性反应及自身免疫疾病治疗药物的应用
CN113736810B (zh) * 2021-09-08 2024-05-24 苏州因特药物研发有限公司 构建体、载体、蛋白、细胞、制备方法、产品及应用
CN114129718B (zh) * 2021-10-19 2024-05-03 华东师范大学 一种用于体内自组装car-t的纳米递送系统及其制备方法和应用
CN114558126B (zh) * 2021-11-04 2024-11-08 苏州大学附属第一医院 序贯输注cd19 car-t和bcma car-t细胞在急性白血病患者免疫介导血小板输注无效中的联合应用
WO2023174405A1 (zh) * 2022-03-18 2023-09-21 广东东阳光药业股份有限公司 Claudin18.2人源化抗体及其应用
EP4551246A1 (en) 2022-07-05 2025-05-14 Neomics Pharmaceuticals LLC Chimeric antigen receptor comprising bcma nanobody linked to a chimeric intracellular signaling domain
WO2024189583A1 (en) * 2023-03-15 2024-09-19 Kyoto Prefectural Public University Corporation Peptide expression constructs and uses thereof
CN116516007B (zh) * 2023-04-18 2024-01-19 华中科技大学同济医学院附属协和医院 Cd19表达的检测方法
CN116536375B (zh) * 2023-06-28 2023-11-10 北京大学深圳研究生院 merocyclophanes类化合物的化学-酶法合成方法及其应用
WO2025160432A1 (en) * 2024-01-26 2025-07-31 Poseida Therapeutics, Inc. Methods and compositions for enhancing in vivo persistence and potency of cell therapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648512A4 (en) * 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
KR100787393B1 (ko) * 2006-03-23 2007-12-21 학교법인 한림대학교 세포 도입성 fk506 결합 단백질의 융합 단백질
US8173792B2 (en) * 2007-02-09 2012-05-08 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells using synthetic small molecules
US8530636B2 (en) * 2008-05-07 2013-09-10 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells in vivo using synthetic small molecules
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN103946242A (zh) * 2011-10-20 2014-07-23 美国卫生和人力服务部 抗cd22嵌合抗原受体
WO2013172926A1 (en) * 2012-05-14 2013-11-21 Yale University Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
ES2758227T3 (es) * 2013-02-15 2020-05-04 Univ California Receptor de antígeno quimérico y métodos de uso del mismo
WO2014152932A1 (en) * 2013-03-14 2014-09-25 Board Of Regents, The University Of Texas System Mirna for treating cancer and for use with adoptive immunotherapies
KR102095700B1 (ko) * 2013-05-14 2020-04-01 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 가공된 키메라 항원 수용체 (car) t-세포의 인간 적용
WO2015028574A1 (en) * 2013-08-28 2015-03-05 Pci Biotech As Compound and method for vaccination and immunisation
KR102339240B1 (ko) * 2013-10-15 2021-12-15 더 스크립스 리서치 인스티튜트 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
EP3245288A1 (en) * 2015-01-12 2017-11-22 Pieris Pharmaceuticals GmbH Engineered t cells and uses therefor
WO2016134284A1 (en) * 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
WO2017180587A2 (en) * 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
TW202508628A (zh) * 2016-07-28 2025-03-01 瑞士商諾華公司 嵌合抗原受體及pd-1抑制劑之組合療法
CN111107866A (zh) * 2017-06-12 2020-05-05 黑曜石疗法公司 用于免疫疗法的pde5组合物和方法

Similar Documents

Publication Publication Date Title
JP2020511529A5 (enrdf_load_stackoverflow)
CN112639102B (zh) 抗间皮素嵌合抗原受体(car)构建体及其用途
US12060394B2 (en) Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
JP2020525536A5 (enrdf_load_stackoverflow)
JP2022130485A (ja) 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント
US11220535B2 (en) Anti-BCMA chimeric antigen receptors
KR20230129983A (ko) 조작된 세포 요법을 위한 표적화된 사이토카인 구축물
TW202023580A (zh) 使用靶特異性融合蛋白進行tcr再程式化之組合物及方法
US20200399393A1 (en) Dimeric Antigen Receptors
CA3177394A1 (en) Method and compositions for cellular immunotherapy
US20220251168A1 (en) Dimeric Antigen Receptors (DAR) that Bind BCMA
JP2025511872A (ja) 多部位受容体及びシグナル伝達複合体
US20220133792A1 (en) Signaling platforms for chimeric antigen receptor t cells
US20200347148A1 (en) Methods for enhancing and maintaining car-t cell efficacy
US20250109182A1 (en) TGF-beta Receptors and Methods of Use
US20240226154A9 (en) Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same
EP4196231A1 (en) Chimeric antigen receptor t cells for treating autoimmunity
CN113646433B (zh) 靶向抗TNF-α抗体的组合物和方法
US20250121007A1 (en) Compositions for the treatment of cancer
WO2023133424A2 (en) Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides
JPWO2021046432A5 (enrdf_load_stackoverflow)